-
|
Reuters –
8:45 AM ET 06/08/2022
FibroGen Inc (FGEN): * FIBROGEN ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN LELANTOS-2, A PHASE 3 CLINICAL STUDY OF PAMREVLUMAB IN DUCHENNE MUSCULAR DYSTROPHY. * FibroGen Inc (FGEN) - TOP-LINE DATA FROM LELANTOS-2 STUDY IS ANTICIPATED IN 2H:2023 Source text for Eikon: Further company coverage:
|
-
|
GlobeNewswire –
7:00 AM ET 06/08/2022
- 73 Ambulatory DMD Patients Enrolled -- Topline Data Anticipated 2H:2023 - FibroGen (FGEN), Inc. today announced completion of patient enrollment for LELANTOS-2, a Phase 3 clinical study of pamrevlumab in patients with ambulatory Duchenne muscular dystrophy.
|
-
|
Business Wire –
10:50 PM ET 05/27/2022
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC, announces that KSF continues its investigation into FibroGen, Inc. (FGEN). On April 6, 2021, the Company disclosed that cardiovascular safety data it had previously submitted for the Phase 3 program of its roxadustat product included post-hoc changes to the stratification factors.
|
-
|
GlobeNewswire –
7:00 AM ET 05/26/2022
FibroGen, Inc. (FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 9 at 1:30pm EDT. A live audio webcast of the event will be available on the Events & Presentations section of the FibroGen Investors webpage at www.fibrogen.com. A replay will be available for approximately 30 days.
|
-
|
PR Newswire –
10:50 PM ET 05/13/2022
NEW ORLEANS, May 13, 2022 Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC, announces that KSF continues its investigation into FibroGen (FGEN), Inc..
|
-
|
Benzinga –
6:22 AM ET 05/11/2022
103 Biggest Movers From Yesterday
|
-
|
Benzinga –
1:48 PM ET 05/10/2022
This article was generated by Benzinga's automated content engine and reviewed by an editor.
|
-
|
Benzinga –
12:00 PM ET 05/10/2022
|
-
|
Reuters –
5:13 PM ET 05/09/2022
FibroGen Inc (FGEN): * FIBROGEN REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS. * Q1 REVENUE ROSE 58 PERCENT TO $60.8 MILLION. * Q1 LOSS PER SHARE $0.68. * Q1 EARNINGS PER SHARE VIEW $-0.83, REVENUE VIEW $28.8 MILLION -- REFINITIV IBES DATA Source text for Eikon: Further company coverage:
|
-
|
GlobeNewswire –
4:01 PM ET 05/09/2022
SAN FRANCISCO, May 09, 2022 -- FibroGen, Inc. (FGEN) today reported financial results for the first quarter 2022 and provided an update on the companys recent developments.
|
-
|
Benzinga –
8:33 AM ET 05/09/2022
Biotech stocks declined yet again in the week ending May 6, dragged lower by macroeconomic concerns following the Federal Reserve's 50-basis-point rate hike. Penny stock and digital therapeutics company Better Therapeutics, Inc. more than doubled despite a lack of any meaningful catalysts. Earnings news flow also continued to move stocks in the space.
|
-
|
Benzinga –
8:18 AM ET 05/09/2022
This article was generated by Benzinga's automated content engine and reviewed by an editor.
|
-
|
Benzinga –
7:08 AM ET 05/09/2022
Don't forget to check out our premarket coverage here .
|
-
|
Benzinga –
4:52 AM ET 05/09/2022
** Atlantica Sustainable is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million. ** NAPCO Security is estimated to report quarterly earnings at $0.07 per share on revenue of $34.66 million. ** GEO Group is projected to report quarterly earnings at $0.10 per share on revenue of $39.26 million.
|
-
|
Benzinga –
12:06 PM ET 05/06/2022
On Friday, 1043 companies hit new 52-week lows. Stocks dropping to new 52-week lows on Friday: Be sure to monitor Benzinga for the news traders need!
|
-
|
Benzinga –
10:07 AM ET 05/06/2022
FibroGen is set to give its latest quarterly earnings report on Monday, 2022-05-09. Analysts estimate that FibroGen will report an earnings per share of $-0.83. FibroGen bulls will hope to hear the company to announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
|
-
|
Business Wire –
3:17 PM ET 05/05/2022
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC, announces that KSF continues its investigation into FibroGen, Inc. (FGEN). On April 6, 2021, the Company disclosed that cardiovascular safety data it had previously submitted for the Phase 3 program of its roxadustat product included post-hoc changes to the stratification factors.
|
-
|
Business Wire –
10:50 PM ET 04/29/2022
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC, announces that KSF has commenced an investigation into FibroGen, Inc. (FGEN). On April 6, 2021, the Company disclosed that cardiovascular safety data it had previously submitted for the Phase 3 program of its roxadustat product included post-hoc changes to the stratification factors.
|
-
|
Benzinga –
3:31 PM ET 04/28/2022
During Thursday, 849 stocks hit new 52-week lows. During the morning session of trading on Thursday, the following stocks broke to new 52-week lows: Be sure to stay with Benzinga for further updates and market-moving news.
|
-
|
GlobeNewswire –
7:00 AM ET 04/25/2022
FibroGen, Inc. (FGEN) will announce its first quarter 2022 financial results on Monday, May 9 after the market close. Conference Call and Audio Webcast Interested parties may access a live audio webcast of the conference call via the FibroGen (FGEN) website at https://fibrogen.gcs-web.com/events-and-presentations/events. Dial-In InformationLive: 658-9081Live: 563-8732Confirmation number: 2487763.
|
Page:
|
Today's and Upcoming Events
-
FGEN to announce Q2 earnings (Unconfirmed)
Past Events (last 90 days)
-
FGEN announced Q1 earnings.
Data provided by Thomson Reuters © 2022
|